Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Czech | Norway | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Johns Hopkins Bloomberg School of Public Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Taeniasis|Neurocysticercosis
Phase 2: Communicable Diseases|Fascioliasis|Trichuriasis
Phase 1: Neurocysticercosis|Filariasis|Healthy Volunteers|Taeniasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT06565507 | P3 |
Not yet recruiting |
Taeniasis|Neurocysticercosis |
2028-03-30 |
|
SIDISI 201221 | P2 |
Not yet recruiting |
Fascioliasis |
2028-03-01 |
|
OXF2 v3.21 | P2 |
Not yet recruiting |
Communicable Diseases|Trichuriasis |
2026-07-01 |
|
HHSN272201300020I | P2 |
Not yet recruiting |
Trichuriasis |
2025-10-01 |